Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status:
Completed
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
This is the first study to test Sym022 in humans. The primary purpose of this study is to see
if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic
solid tumor malignancies or lymphomas that are refractory to available therapy or for which
no standard therapy is available.